Real-World Clinical Evidence of Novel Antibiotics
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (15 November 2022) | Viewed by 305
Special Issue Editors
Interests: real-world studies; antimicrobial stewardship; hospital-acquired infections; clinical epidemiology; MRSA
Interests: treatment; tropical diseases; clinical assessment; infection; infectious disease epidemiology; PCR; emerging infectious diseases; immunology of infectious diseases; epidemiology; HIV
Special Issue Information
Dear Colleagues,
Several novel antibiotics were developed in the past 10 years to combat multi-drug resistant pathogens. They were approved upon randomized clinical trials (RCT) to demonstrate the efficacy and safety for a specific infection in a controlled environment. On the other hand, real-world evidence (RWE) in the form of post-marketing studies can help to evaluate how the novel antibiotic performs in a diverse population outside of that assessed in RCT. They aim to bridge the gap between clinical trials and routine clinical practice.
In this Special Issue, we aim to RWE of antimicrobials in a diverse, challenging patient population that are not commonly represented in RCT such as elderly, non-approved indications, those with augmented renal clearance, as well immunocompromised patients. RWE includes registries, case series, and comparative studies.
This fits the scope of antibiotics because it adds to the existing evidence regarding the use of novel antibiotics
Dr. Sara Alosaimy
Prof. Dr. Antonio Cascio
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- real-world
- novel antibiotics
- elderly
- immunocompromised
- renal adjustment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
